Acera Therapeutics offers an AI‑driven drug discovery platform that integrates computational modeling, high‑throughput screening, and proprietary biomarker assays to identify and de‑risk therapeutic candidates early in development. The service provides end‑to‑end data management, in‑vitro/in‑vivo validation, and regulatory‑ready documentation to help pharma, biotech, and academic teams accelerate preclinical candidate selection.
Funding
Funding not disclosed
Founders
Product
Problem
Developing new therapeutics is costly and time‑consuming, with many promising drug candidates failing in late‑stage development due to insufficient preclinical validation and suboptimal target selection.
Solution
Acera Therapeutics provides an integrated drug discovery platform that combines advanced computational modeling, high‑throughput screening, and proprietary biomarker assays to identify and de‑risk therapeutic candidates early in the pipeline. The company leverages AI‑driven target identification and structure‑based design to generate optimized lead compounds with improved efficacy and safety profiles. In‑vitro and in‑vivo validation services are offered through a network of specialized laboratories, accelerating the transition from hit identification to preclinical candidate. Acera also supplies data‑rich reports and regulatory‑ready documentation to streamline IND filing and reduce time to market.
Target Audience
Acera Therapeutics serves pharmaceutical companies, biotech firms, and academic research groups seeking to accelerate early‑stage drug discovery and improve candidate success rates.
Features
- AI‑powered target discovery using multi‑omics datasets and machine‑learning algorithms
- Structure‑based drug design with cloud‑based molecular modeling and docking tools
- High‑throughput screening of diverse chemical libraries integrated with automated assay pipelines
- Proprietary biomarker panels for early safety and efficacy assessment in cellular and animal models
- End‑to‑end data management platform delivering real‑time analytics and regulatory‑compliant reporting
- Flexible service models ranging from project‑based collaborations to fully managed discovery programs